首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1341913

全球人造血液市场（~2028）

Artificial Blood: Global Markets to 2028

出版日期: 2023年08月29日 | 出版商:

BCC Research | 英文 120 Pages | 订单完成后即时交付

价格

简介目录图表

全球人造血液市场规模预计将从 2022 年的 2390 万美元和 2023 年的 2610 万美元增长到 2028 年的 4050 万美元，预测期内年复合成长率为 9.2%。

本报告调查了全球人造血液市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和地区的详细分析、产品分析以及技术和专利趋势、竞争形势、概况主要企业等

人类血液问题
人造血液的新需求
人造血液：有助于解决感染疾病风险
人造血液：减轻献血者血液供应负担
人造血液：需要应对血液系统的意外需求
开发人造血液製品的障碍
人造血液的理想特性
人造血液优于人类血液
用途
外科手术
紧急復苏
短期使用
案例比人血更有效
因宗教信仰而拒绝
人造血液开发的课题

第4章市场动态

促进因素
输血需求增加
与输血相关的风险和课题
血液供应不足
障碍
产品核可率低
产品验收
产品定价
机会
COVID-19 的影响

第5章人造血液：按来源分类

人造血液是由人类血液研製而成
由动物血液研製而成的人造血液
利用基因重组技术开发的人造血液
表面修饰血红蛋白
交联血红蛋白
聚合血红蛋白
封装
基因工程重组血红蛋白
天然血红蛋白

第6章人造血液：按类型

全氟化碳乳液
全氟化碳的一般性质
乳液选择
全氟化碳乳液的历史发展
第一代PFC
第二代PFC
第三代PFC
血红蛋白氧载体 (HBOC)
HBOC的一般特征
历史事件：血红蛋白溶液

第7章市场预估

人造血液的潜在市场
人造血液市场：按来源分类
血液（动物/人）
合成聚合物
人造血液市场：按类型
血红蛋白氧载体
全氟化碳产品
人造血液市场：按地区
北美
欧洲
新兴市场

第8章新技术和发展

概述
新技术
纳米胶囊技术
干细胞
其他正在进行的血液替代品研究

第9章产品分析

产品安全
产品功效
产品成本
法律影响
部分在研产品的产品分析
Hemopure
HemO2life
HemoTech
NanO2 (DDFPe)
Sanguinate
Vidaphor
临床试验
一些处于临床前和早期 I 期阶段的产品的描述
ErythroMer
Hemoglobin vesicles
OxyVita
OxyBridge

第10章专利分析

FDA法规
FDA 良好生产规范和报告
专利分析

第11章竞争资讯

战略发展
竞争分析

第12章公司简介

AURUM BIOSCIENCES
ERYPHARM
HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
HEMARINA
KALOCYTE INC.
NANO SANGUIS SA
NUVOX PHARMA LLC.
PROLONG PHARMACEUTICALS, LLC
RED C BIOTECH
VIRTECH BIO

简介目录图表

Product Code: BIO164B

Highlights:

The global artificial blood market reached $23.9 million in 2022, should reach $26.1 million by 2023 and $40.5 million by 2028 with a compound annual growth rate (CAGR) of 9.2% during the forecast period of 2023-2028.

Report Scope:

The scope of this study encompasses an investigation of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status, and the potential commercial demand for artificial blood products. The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.

Report Includes:

41 tables
An overview of the global markets for artificial blood
Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Highlights of the market potential and characterization of artificial blood market by product, application, and region
Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
Coverage of recent advances, emerging technologies, and developments of the industry
Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
Company profiles of major players within the industry, including Hemarina, VirTechBio, and NuvOx Pharma

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Methodology
Information Sources
Geographic Breakdown

Chapter 2 Summary and Highlights

Market Overview

Chapter 3 Market Overview

Introduction
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing with the Risks of Infection
Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Applications
Surgeries
Emergency Resuscitation
For Short-term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Challenges in Artificial Blood Development

Chapter 4 Market Dynamics

Drivers
Increasing Demand for Blood Transfusions
Risks and Challenges Associated with Blood Transfusions
Shortage of Blood Supply
Barriers
Low Rate of Product Approvals
Product Acceptance
Product Pricing
Opportunities
Impact of COVID-19

Chapter 5 Artificial Blood by Source

Introduction
Artificial Blood Developed from Human Blood
Artificial Blood Developed from Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin
Encapsulation
Genetically Engineered Recombinant Hemoglobin
Natural Hemoglobin

Chapter 6 Artificial Blood by Type

Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of PFCs
Second Generation of PFCs
Third Generation of PFCs
Hemoglobin-based Oxygen Carriers
General Characteristics of HBOCs
Historical Events: Hemoglobin Solutions

Chapter 7 Market Estimation

Introduction
Potential Market for Artificial Blood
Artificial Blood Market, by Source
Blood (Animal/Human)
Synthetic Polymers
Artificial Blood Market, by Type
Hemoglobin-based Oxygen Carriers
Perfluorocarbon-based Products
Artificial Blood Market, by Region
North America
Europe
Emerging Markets

Chapter 8 Emerging Technologies and Developments

Overview
Emerging Technologies
Nanocapsule Technology
Stem Cells
Other Ongoing Research for Blood Substitutes

Chapter 9 Product Analysis

Introduction
Product Safety
Product Effectiveness
Product Cost
Legal Implications
Product Analysis of Some of the Products Under Development
Hemopure
HemO2life
HemoTech
NanO2 (DDFPe)
Sanguinate
Vidaphor
Clinical Trials
Product Description of Some of the Products in Preclinical and Early Phase I Stage
ErythroMer
Hemoglobin vesicles
OxyVita
OxyBridge

Chapter 10 Patent Analysis

Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Analysis

Chapter 11 Competitive Intelligence

Strategic Developments
Competitive Analysis

Chapter 12 Company Profiles

AURUM BIOSCIENCES
ERYPHARM
HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
HEMARINA
KALOCYTE INC.
NANO SANGUIS S.A
NUVOX PHARMA LLC.
PROLONG PHARMACEUTICALS, LLC
RED C BIOTECH
VIRTECH BIO

简介目录图表

List of Tables

Summary Table : Global Market for Artificial Blood, Through 2028
Table 1 : Historical Events Related to Blood Transfusion, 1628-2022
Table 2 : Potential Benefits and Application Areas of Artificial Blood
Table 3 : Average Number of Blood Units Required During Particular Medical Conditions
Table 4 : The Challenges Associated with the Development of Artificial Blood
Table 5 : Common Challenges to the Blood Transfusion Continuum in LMICs.
Table 6 : Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
Table 7 : Pros and Cons of Artificial Blood Developed from Human Blood
Table 8 : Pros and Cons of Artificial Blood Developed from Animal Blood
Table 9 : Pros and Cons of Artificial Blood Developed from Recombinant Blood
Table 10 : Summary of Acellular Hb-Based Oxygen Carriers
Table 11 : Examples of Hemoglobin-based Oxygen Carrier Products and Approval Status
Table 12 : Potential Clinical Applications of Oxygen Carriers
Table 13 : Composition of PFC Emulsion-Based Artificial Blood Products
Table 14 : First Generation Perfluorocarbon Emulsions Used in Medicine and Biology
Table 15 : Comparative Study of Second-Generation PFCs
Table 16 : PFC Emulsion Products and Current Status
Table 17 : Comparative Study Between RBCs and HBOCs
Table 18 : HBOC Solutions Transfusion: Side Effects and Possible Causes
Table 19 : Examples of HBOC Products Developed, by Various Companies
Table 20 : Global Market for Artificial Blood, Through 2028
Table 21 : Current Cell Sources and Strategies for Ex-vivo RBC Generation
Table 22 : List of Discontinued Blood Substitutes
Table 23 : Hemopure: Raw Material and Method Overview
Table 24 : Hemopure: Product Characteristics
Table 25 : Hemopure: Advantages and Disadvantages
Table 26 : Summary of Clinical Trials of Hemopure (HBOC-201), 2023
Table 27 : HemO2life: Raw Material and Method
Table 28 : HemO2life: Advantages and Disadvantages
Table 29 : HemO2life: Product
Table 30 : Ex vivo, In vivo and Clinical Studies involving HemO2life (M101) Use
Table 31 : Hemotech: Raw Material and Method Overview
Table 32 : HemoTech: Advantages and Disadvantages
Table 33 : NanO2 (DDFPe): Raw Material and Method Overview
Table 34 : NanO2 (DDFPe): Advantages and Disadvantages
Table 35 : NanO2 (DDFPe): Clinical Trials, 2023
Table 36 : Sanguinate: Raw Material and Method Overview
Table 37 : Sanguinate: Advantages and Disadvantages
Table 38 : Sanguinate: Clinical Trials, 2023
Table 39 : Vidaphor: Raw Material and Method Overview
Table 40 : Vidaphor: Advantages and Disadvantages
Table 41 : Vidaphor: Clinical Trials, 2023